Comparison of Attack Data between Rituximab and Inebilizumab in N-MOmentum Study
10 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What was the trend in CD20+ B-cell counts among all participants with prior rituximab use during the open-label period (>Week 28)?

Decreased

How was UPLIZNA generally tolerated in the study?

Well

What was the percentage of participants with prior rituximab use who experienced treatment-related adverse events?

53%

How many participants with prior rituximab use experienced treatment discontinuation due to adverse events?

<p>1</p> Signup and view all the answers

What percentage of participants with no prior rituximab use experienced serious adverse events?

<p>18%</p> Signup and view all the answers

Were there any deaths reported among the 17 rituximab-experienced participants?

<p>No</p> Signup and view all the answers

What was the percentage of participants with prior rituximab use who experienced grade >3 adverse events?

<p>29%</p> Signup and view all the answers

How many rituximab-experienced participants had serious events that were also related to UPLIZNA?

<p>2</p> Signup and view all the answers

Did prior rituximab use appear to be associated with an increased rate of serious or grade >3 infections in the study?

<p>No</p> Signup and view all the answers

What was the total number of participants with prior rituximab use in the study?

<p>17</p> Signup and view all the answers

More Like This

Physics Chapter 6: Momentum Flashcards
32 questions
Physics of Angular Momentum
22 questions

Physics of Angular Momentum

BeneficentHonor6192 avatar
BeneficentHonor6192
Physics Momentum & Collisions Concepts
17 questions
Angular Momentum and Impulse Concepts
26 questions
Use Quizgecko on...
Browser
Browser